JP2011513464A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513464A5 JP2011513464A5 JP2010550176A JP2010550176A JP2011513464A5 JP 2011513464 A5 JP2011513464 A5 JP 2011513464A5 JP 2010550176 A JP2010550176 A JP 2010550176A JP 2010550176 A JP2010550176 A JP 2010550176A JP 2011513464 A5 JP2011513464 A5 JP 2011513464A5
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- bisphosphonate
- minutes
- solution
- erythrocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003743 Erythrocytes Anatomy 0.000 claims 16
- 239000000725 suspension Substances 0.000 claims 14
- VYLDEYYOISNGST-UHFFFAOYSA-N Bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 claims 10
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 claims 9
- 150000004663 bisphosphonates Chemical class 0.000 claims 9
- 210000003324 RBC Anatomy 0.000 claims 2
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000375 suspending agent Substances 0.000 claims 2
- 229960004276 zoledronic acid Drugs 0.000 claims 2
- 229940062527 Alendronate Drugs 0.000 claims 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229940015872 Ibandronate Drugs 0.000 claims 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N Incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims 1
- 229950006971 Incadronic acid Drugs 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical group NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229940089617 Risedronate Drugs 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229950010733 neridronic acid Drugs 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960000759 risedronic acid Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000005429 turbidity Methods 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
Claims (12)
- 骨転移の予防および治療のための医薬として使用するための、ビスホスホネートを封入した赤血球の懸濁剤であって、このときビスホスホネートが第二世代または第三世代のビスホスホネートである、懸濁剤。
- ビスホスホネートを封入した赤血球が、骨髄のターゲティングを増進するように作用物質による化学処理を受けている、請求項１に記載の赤血球の懸濁剤。
- 化学処理が、ビス（スルホスクシンイミジル）スベレート（ＢＳ３）の溶液で行なわれる、請求項２に記載の赤血球の懸濁剤。
- ビスホスホネートを封入した赤血球の懸濁剤を、１０分〜１時間、特に１５分〜４５分、好ましくは２０〜４０分、一般に３０分程度の期間、ＢＳ３と接触させる、請求項３に記載の赤血球の懸濁剤。
- ＢＳ３とのインキュベーションが周囲温度で行なわれる、請求項３または４に記載の赤血球の懸濁剤。
- ビスホスホネートを収容した赤血球の懸濁剤を、ＢＳ３とのインキュベーションの前に、適切な緩衝液、好ましくはＰＢＳで洗浄する、請求項３〜５のいずれか１項に記載の赤血球の懸濁剤。
- ビスホスホネートを封入した赤血球の懸濁剤を、ＢＳ３の溶液と接触させる前に、０．５×１０６〜５×１０６細胞／μｌ、好ましくは１×１０６〜３×１０６細胞／μｌの濃度にする、請求項３〜６のいずれか１項に記載の赤血球の懸濁剤。
- ＢＳ３の溶液を用いて、懸濁剤中に０．１〜６ｍＭ、好ましくは０．５〜３ｍＭ、よりさらに良好には約１ｍＭの最終ＢＳ３濃度を得る、請求項３〜７のいずれか１項に記載の赤血球の懸濁剤。
- ２８０〜３２０ｍＯｓｍのオスモル濃度および７．２〜７．６、好ましくは７．４のｐＨを有する緩衝化されたＢＳ３溶液を用いる、請求項３〜８のいずれか１項に記載の赤血球の懸濁剤。
- ＢＳ３の溶液がグルコースおよびリン酸緩衝液を含む、請求項９に記載の赤血球の懸濁剤。
- ビスホスホネートが、パミドロネート、特に二ナトリウム形のもの、アレンドロネート、インカドロネート、イバンドロネート、ネリドロネート、リセドロネートおよびゾレドロネートから選択される、請求項１〜１０のいずれか１項に記載の赤血球の懸濁剤。
- ビスホスホネートがゾレドロネートである、請求項１〜１０のいずれか１項に記載の赤血球の懸濁剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0851521A FR2928270B1 (fr) | 2008-03-10 | 2008-03-10 | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os |
| FR0851521 | 2008-03-10 | ||
| PCT/EP2009/052792 WO2009112493A1 (en) | 2008-03-10 | 2009-03-10 | Formulation and method for the prevention and treatment of bone metastases or other bone diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513464A JP2011513464A (ja) | 2011-04-28 |
| JP2011513464A5 true JP2011513464A5 (ja) | 2011-06-16 |
| JP6034001B2 JP6034001B2 (ja) | 2016-11-30 |
Family
ID=39865428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550176A Expired - Fee Related JP6034001B2 (ja) | 2008-03-10 | 2009-03-10 | 骨転移または他の骨疾患の予防および治療のための配合物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20110014171A1 (ja) |
| EP (1) | EP2249816B1 (ja) |
| JP (1) | JP6034001B2 (ja) |
| KR (1) | KR101604451B1 (ja) |
| CN (1) | CN101965182B (ja) |
| AU (1) | AU2009224681B2 (ja) |
| CA (1) | CA2718028C (ja) |
| ES (1) | ES2544967T3 (ja) |
| FR (1) | FR2928270B1 (ja) |
| HK (1) | HK1152883A1 (ja) |
| IL (1) | IL207713A (ja) |
| PL (1) | PL2249816T3 (ja) |
| WO (1) | WO2009112493A1 (ja) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| DK2459176T3 (en) | 2009-07-31 | 2017-12-04 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| CN108129554A (zh) | 2010-08-10 | 2018-06-08 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| FR3005420B1 (fr) * | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| WO2015073587A2 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| NZ723879A (en) | 2014-02-21 | 2018-03-23 | Ecole Polytechnique Fed Lausanne Epfl | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| DK3125927T3 (da) | 2014-04-01 | 2021-04-19 | Rubius Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulering |
| JP2016025177A (ja) * | 2014-07-18 | 2016-02-08 | トヨタ自動車株式会社 | スイッチング素子 |
| CA3009063A1 (en) | 2016-01-11 | 2017-07-20 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| ES2867230T3 (es) * | 2016-10-26 | 2021-10-20 | Biointelligence Systems S L | Composición bioactiva ósea y usos de la misma |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| CN110568114B (zh) * | 2019-08-29 | 2021-12-28 | 福州佳宸生物科技有限公司 | 唑来膦酸和利塞膦酸的固相微萃取-高效液相色谱在线联用检测方法 |
| WO2021228832A1 (en) | 2020-05-11 | 2021-11-18 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
| CN112790155A (zh) * | 2021-02-01 | 2021-05-14 | 华中科技大学同济医学院附属协和医院 | 一种验证sag预防环境异常相关性骨发育不良的方法 |
| CN115400145B (zh) * | 2021-05-26 | 2024-04-30 | 北京罗诺强施医药技术研发中心有限公司 | 治疗和预防骨质疏松症的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2529463B1 (fr) * | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
| FR2678512B1 (fr) * | 1991-07-03 | 1995-06-30 | Novacell | Machine a internaliser. |
| EP0882448B1 (en) * | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Method of encapsulating biologically active agents within erythrocytes and apparatus therefor |
| CN1771972A (zh) * | 2004-11-09 | 2006-05-17 | 胡才忠 | 氯屈膦酸脂质体及其制剂 |
| US20070218116A1 (en) * | 2006-03-14 | 2007-09-20 | Schwendener Reto A | Compositions and methods for the treatment of tumors and tumor metastases |
| WO2008016172A1 (fr) * | 2006-08-04 | 2008-02-07 | Kurume University | Inhibiteur de métastase |
| US20100316620A1 (en) * | 2008-02-13 | 2010-12-16 | Vanessa Bourgeaux | Formulation and Method for the Prevention and Treatment of Skeletal Manifestation of Gaucher's Disease |
-
2008
- 2008-03-10 FR FR0851521A patent/FR2928270B1/fr not_active Expired - Fee Related
-
2009
- 2009-03-10 CN CN2009801083776A patent/CN101965182B/zh not_active Expired - Fee Related
- 2009-03-10 KR KR1020107019901A patent/KR101604451B1/ko active IP Right Grant
- 2009-03-10 WO PCT/EP2009/052792 patent/WO2009112493A1/en active Application Filing
- 2009-03-10 US US12/921,962 patent/US20110014171A1/en not_active Abandoned
- 2009-03-10 EP EP20090720545 patent/EP2249816B1/en active Active
- 2009-03-10 CA CA2718028A patent/CA2718028C/en not_active Expired - Fee Related
- 2009-03-10 JP JP2010550176A patent/JP6034001B2/ja not_active Expired - Fee Related
- 2009-03-10 ES ES09720545.4T patent/ES2544967T3/es active Active
- 2009-03-10 PL PL09720545T patent/PL2249816T3/pl unknown
- 2009-03-10 AU AU2009224681A patent/AU2009224681B2/en not_active Ceased
-
2010
- 2010-08-19 IL IL207713A patent/IL207713A/en active IP Right Grant
-
2011
- 2011-07-07 HK HK11107026.0A patent/HK1152883A1/xx not_active IP Right Cessation
-
2013
- 2013-07-08 US US13/936,848 patent/US20140010795A1/en not_active Abandoned
-
2014
- 2014-08-27 US US14/470,244 patent/US20140363413A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513464A5 (ja) | ||
| Cui et al. | Characterisation of matrix vesicles in skeletal and soft tissue mineralisation | |
| Otto et al. | Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism | |
| Garcia-Sanchez et al. | Enhancing survival, engraftment, and osteogenic potential of mesenchymal stem cells | |
| Ekdahl et al. | Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross‐talk act as a linchpin in the events leading to thromboinflammation | |
| Godoy-Gallardo et al. | Antibacterial properties of hLf1–11 peptide onto titanium surfaces: A comparison study between silanization and surface initiated polymerization | |
| Dunford et al. | Structure–activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase | |
| Kobayashi et al. | Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice | |
| JP6034001B2 (ja) | 骨転移または他の骨疾患の予防および治療のための配合物および方法 | |
| Pathak et al. | The osteocyte as the new discovery of therapeutic options in rare bone diseases | |
| Yang et al. | Intrinsic Apyrase‐Like Activity of Cerium‐Based Metal–Organic Frameworks (MOFs): Dephosphorylation of Adenosine Tri‐and Diphosphate | |
| Stevenson et al. | Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages | |
| Onasoga‐Jarvis et al. | Thrombin generation and fibrin formation under flow on biomimetic tissue factor‐rich surfaces | |
| Ha et al. | Nano-hydroxyapatite stimulation of gene expression requires Fgf receptor, phosphate transporter, and Erk1/2 signaling | |
| Puljula et al. | Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters | |
| BR112014004554A2 (pt) | sistemas e processos para encapsulamento de cápsulas | |
| Wang et al. | Influence of solution chemistry and soft protein coronas on the interactions of silver nanoparticles with model biological membranes | |
| RU2015152127A (ru) | Способ стабилизации суспензий эритроцитов с инкапсулированным активным ингредиентом и их получение | |
| Müller et al. | Development of a morphogenetically active scaffold for three‐dimensional growth of bone cells: biosilica–alginate hydrogel for SaOS‐2 cell cultivation | |
| Xu et al. | Multifunctional biomaterial coating based on bio-inspired polyphosphate and lysozyme supramolecular nanofilm | |
| Chen et al. | Modeling the interaction of seven bisphosphonates with the hydroxyapatite (100) face | |
| Li et al. | Fabrication of endothelial progenitor cell capture surface via DNA aptamer modifying dopamine/polyethyleneimine copolymer film | |
| CN111658820A (zh) | 一种促进骨再生的可注射水凝胶及其制备方法 | |
| Liu et al. | Phosphorylated chitosan hydrogels inducing osteogenic differentiation of osteoblasts via JNK and p38 signaling pathways | |
| Kaladhar et al. | Supported cell mimetic monolayers and their interaction with blood |